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Abstract
Background
The current cost of Xpert MTB RIF (Xpert) consumables is such that algorithms are needed
to select which patients to prioritise for testing with Xpert.
Objective
To evaluate two algorithms for prioritisation of Xpert in primary health care settings in a high
TB and HIV burden setting.
Method
Consecutive, presumptive TB patients with a cough of any duration were offered either
Xpert or Fluorescence microscopy (FM) test depending on their CXR score or HIV status. In
one facility, sputa from patients with an abnormal CXR were tested with Xpert and those
with a normal CXR were tested with FM (“CXR algorithm”). CXR was scored automatically
using a Computer Aided Diagnosis (CAD) program. In the other facility, patients who were
HIV positive were tested using Xpert and those who were HIV negative were tested with FM
(“HIV algorithm”).
Results
Of 9482 individuals pre-screened with CXR, Xpert detected TB in 2090/6568 (31.8%) with
an abnormal CXR, and FM was AFB positive in 8/2455 (0.3%) with a normal CXR. Of 4444
pre-screened with HIV, Xpert detected TB in 508/2265 (22.4%) HIV positive and FM was
AFB positive in 212/1920 (11.0%) in HIV negative individuals. The notification rate of new
bacteriologically confirmed TB increased; from 366 to 620/ 100,000/yr and from 145 to 261/
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100,000/yr at the CXR and HIV algorithm sites respectively. The median time to starting TB
treatment at the CXR site compared to the HIV algorithm site was; 1(IQR 1-3 days) and 3
(2-5 days) (p<0.0001) respectively.
Conclusion
Use of Xpert in a resource-limited setting at primary care level in conjunction with pre-
screening tests reduced the number of Xpert tests performed. The routine use of Xpert re-
sulted in additional cases of confirmed TB patients starting treatment. However, there was
no increase in absolute numbers of patients starting TB treatment. Same day diagnosis and
treatment commencement was achieved for both bacteriologically confirmed and empirical-
ly diagnosed patients where Xpert was used in conjunction with CXR.
Introduction
There has been an increase in the notification of smear negative pulmonary TB especially in
high HIV prevalent settings.[1–4] This is largely due to the diagnostic challenge posed by HIV
associated TB which includes pauci-bacillary disease resulting in a low sensitivity of sputum
smear microscopy in this population.[3, 5–7]In contrast to the pre-HIV era, smear negative TB
patients in high HIV prevalence settings have been observed to have poor outcomes and these
may be as a result of delayed diagnosis or incorrect diagnosis of TB. [8–10]In recognition of
these challenges, the World Health Organisation (WHO) has issued several guidelines aimed
at improving the diagnosis of TB in high HIV prevalence settings.[2, 11–14]
In 2006 and 2007, the WHO issued guidelines for improving diagnosis of smear negative
TB in high HIV prevalence settings and on use of liquid culture in low and middle income
countries.[2, 13] These guidelines recommended early use of Chest X-ray (CXR) and use of
culture in smear negative HIV positive presumptive TB patients.[1]Implementation of these
guidelines faced ongoing challenges such as the limited access to culture and CXR. [15] Apart
from high cost, need for specialised laboratories, and specialised training, the long turnaround
time(TAT) to culture results limited the impact of culture in on of TB. CXR use was limited by
non-availability at peripheral facilities as well as by the difficulty in interpreting results largely
due to scarce qualified staff with capacity to correctly interpret CXRs.[16].In 2010, the WHO
issued the first guidelines for use of Xpert MTB RIF (Xpert) in high burden TB and HIV set-
tings in further recognition of the diagnostic challenge TB still posed in these settings.[12] Re-
placing culture with Xpert could result in shortening the TAT especially if placed at peripheral
facilities.[17–19]The challenges of CXR availability and interpretation issues could be resolved
through use of novel imaging techniques that might replace conventional radiography. The re-
cent advances in digital technology with the use of computer aided diagnostic (CAD) systems
may potentially overcome the challenges that have faced use of CXR in resource constrained
settings.[16, 20–22]Digital CXR technology with automated scoring is now available. [23]
In view of the considerable cost of Xpert which limits the extended use of Xpert especially in
resource constrained settings, guidelines for Xpert recommended use on pre-selected patients
considered to be at high risk for TB and in whom use would most likely have the most impact.
[11] The cost of using Xpert can also be minimised through use in conjunction with other
screening tools that identify high risk patients such as CXR.[24, 25]The initial guidelines rec-
ommended Xpert as an initial diagnostic test for suspected HIV associated TB and for sus-
pected MDR TB. Later, the guidelines were revised to include use of Xpert as a second line test
Algorithms for Xpert MTB/RIF
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in patients with smear negative results or those with an abnormal CXR without HIV infection
or those with unknown status but not seriously ill as a conditional recommendation.[11] Apart
from shortening the TAT for results availability to one day, the use of Xpert was also expected
to increase TB case detection and improve outcomes of TB patients. There is mixed evidence
available now showing that whilst use of Xpert increases accurately diagnosed TB, its impact
on case detection may be undermined by continuing empirical treatment of TB. [18, 19, 26–28]
The WHO guidelines for use of Xpert were based on evidence from initial multicentre dem-
onstration studies and were based largely on sensitivity and specificity data.[29, 30]Implemen-
tation of Xpert in resource constrained settings requires evidence to inform policy, especially
when used in primary health care facilities. Further evidence is required on how to use Xpert
within the recommendedWHO guidelines.[11, 15]In this study, we conducted implementation
research to inform the prioritisation of patients for testing with Xpert in a high TB HIV burden
resource-constrained setting. Two algorithms were assessed for TB detection, using either HIV
infection or CXR as entry points to accessing Xpert diagnosis.
Ethics Statement
The study had ethical approval from the University of Zambia biomedical research ethics com-
mittee. The requirement to obtain individual written informed consent was waived for pre-
sumptive TB patients being screened as part of the case finding activities, as this was part of
routine health care and all modalities of TB diagnosis included are currently recommended as
best practice. Oral informed consent was obtained from presumptive TB patients at the time of
registration to the presumptive TB register.
Methods
Study setting and study population
The study was conducted in two primary health care facilities in Lusaka, Zambia. The health fa-
cilities are located in peri—urban Lusaka and offer services to a population with a high burden
of TB and HIV. In one facility, an algorithm using computerised scoring of digital chest radiog-
raphy (CXR) as a pre- screening tool to select samples to test with Xpert was used. In the other
facility, an algorithm using HIV testing as pre- screening tool was implemented. The facilities
were selected based on their high burden of TB and HIV as well as based on the low proportion
of confirmed cases starting TB treatment. The CXR algorithm site notified 2207 TB patients,
with an overall notification rate of 1711 /100,000 population (based on an estimated population
size of 129,000) in 2010. Of all notified patients, 1881 (85.2%) had pulmonary TB of which 533
(28.3%) were smear positive. On the other hand, the HIV algorithm site notified 831 patients,
with an overall notification rate of 681/100,000 population (for an estimated population size of
122,000) in 2010. Patients notified with pulmonary TB were 568 (68.4%) and of these 179
(31.5%) had smear positive pulmonary TB. The HIV co infection rates among notified TB pa-
tients were over 68% in both facilities. According to the latest population estimates, in 2012,
the CXR algorithm site had an estimated population of 161,000 whilst the HIV algorithm site
had a population of 145,200 (personal communication sister’s in charge).
The study population included individuals that presented to the health facilities and met the
definition of a presumptive TB patient. In this study, in line with the updated screening strategy
proposed by WHO[11, 31] a presumptive TB patient was defined as any individual with a
cough of any duration who was able to submit a sputum sample. Algorithm data presented was
collected between March 2012 and March 2014 from consecutive patients presenting to the fa-
cilities during the study period. Data for comparison of notification included all notified TB
register data for these 2 facilities from 2nd quarter 2010 through to 1st quarter 2014.
Algorithms for Xpert MTB/RIF
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Study Objectives
The main objective of the study was to evaluate 2 algorithms for prioritisation of patients for
Xpert testing. The main outcomes of interest were: 1) to assess how pre-screening with CXR
alone, CXR and HIV in combination and HIV alone would impact on the numbers needed to
be tested with Xpert to detect TB; 2)to determine additional bacteriologically confirmed TB
cases starting TB treatment; 3) to measure changes in notification rates after introduction of
Xpert; 3) to assess the time to starting TB treatment for both bacteriologically confirmed and
empirically treated patients and how this changed with availability of CXR;4) to determine the
proportion with empirical TB treatment and 5) to determine the proportion of cases that are
missed as a result of following the HIV algorithm.
Study design and procedures
This was a prospective study. As part of the study, mobilisation activities were conducted in
the community aimed at raising community awareness of tuberculosis and encouraging com-
munity members to present for TB screening. Mobilisation activities were conducted through-
out the duration of the study. Details of the mobilisation activities have been described
elsewhere.[32] Briefly, mobilisation activities were conducted through use of drama, mega
phone announcement, distribution of flyers, health talks and door-to-door visits. Community
members were encouraged to present to the health facility if they had a cough of any duration.
Open access points were established at both facilities and these allowed patients to present di-
rectly to TB services without queuing up in the general outpatient clinic before being investi-
gated for TB. A presumptive TB register was maintained at the open access point and all
patients presenting for TB diagnosis were registered and allocated a unique presumptive TB
patient number.
CXR algorithm procedures
At the CXR algorithm study site, a digital CXR unit (Odelca-DR, Delft Imaging Systems, the
Netherlands) located within the facility premises was used to perform CXRs of presumptive TB
patients. Presumptive TB patients were offered a CXR, followed by HIV counselling and test-
ing. The CXRs were automatically scored by a Computer Aided Diagnostic Program (CAD)
developed to detect abnormalities suggestive of TB. (CAD4TB, version 1.08, Diagnostic Image
Analysis Group, Nijmegen, the Netherlands) [23, 33]. The software was trained on digital X-
rays obtained at two sites with a high TB prevalence in Sub-Saharan Africa. Details of the de-
velopment of this software have been described elsewhere. [34–36] The CAD program scores
the x-ray on an abnormality score ranging between 0 and 100, and a higher score is indicative
of more severe abnormalities. [23] CXR data previously collected from the same population
was used to select an appropriate threshold for the CAD score.[32] A threshold of 61 was cho-
sen based on the area under the receiver operating curve (ROC). The ROC was constructed
with a test set of CXRs collected in the same population using a radiological reference. We have
previously described a proof of principle prospective study where we compared consecutive
presumptive TB patients offered both Xpert and FM regardless of their CXR score to assess the
sensitivity and specificity of the CAD program at the chosen thresholds. [32]. In this proof of
principle study, the negative predictive value of CAD for TB detection was 100% and the posi-
tive predictive value was 33% using Xpert as a reference standard.
For this study, using the same threshold of 61 as the cut off, a prospective study of consecu-
tive presumptive TB patients presenting to the facility were enrolled over a period of 2 years.
Patients were tested with Xpert if their CXR was scored as abnormal (CAD score 61–100) and
Algorithms for Xpert MTB/RIF
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FM testing was done if their CXR was normal (CAD score 0–60) regardless of their HIV status.
Individuals that did not get a CXR done were tested with Xpert (Fig 1).
HIV algorithm procedures
The HIV algorithm was designed in line with the WHO recommendations for use of Xpert in
high TB HIV burden settings.[11, 12]In these settings, Xpert testing is strongly recommended
as an initial diagnostic test in individuals suspected of HIV and TB co-infection. Working on
this premise, presumptive TB patients presenting to this facility were offered counselling and
opt out HIV testing, followed by Xpert test for those who were HIV positive and smear micros-
copy testing for those who were HIV negative. Additionally, HIV status unknown (those who
declined to test for HIV) were also offered testing with Xpert.
In order to understand how many are missed by testing those who are HIV negative with
FM, over a period of two months, consecutive presumptive TB patients were offered both
Xpert and FM regardless of their HIV status.
Sputum testing and TB diagnosis
Xpert MTB/ RIF (Cepheid, Inc., Sunnyvale, CA, USA) instruments and LED-FMmicroscopes
were placed in both primary health care facility laboratories. Patients being tested with Xpert
were requested to submit a spot sample, whilst those being tested with FM were requested to
submit a spot and morning sample in line with the National TB Program guidelines. Xpert and
FM testing were done according to standard operating procedures.[37, 38]Patients that did not
have TB detected by either method were referred for clinical review and assessment, which in-
cluded physical examination and review of CXR where available.
TB diagnosis was defined as bacteriologically confirmed TB where Xpert detected MTB or
FM detected Acid Fast bacilli, or as clinical TB (empirical TB diagnosis) where TB treatment
was commenced in a patient who did not have TB detected by either diagnostic method.
Data capturing and analysis
All patients presenting to the open access points were registered and assigned a unique patient
identifier number using an electronic data base. The database was designed and developed
using Microsoft SQL Server 2005 (Microsoft Corporation, RedmondWA, USA) as the back
end and Microsoft Visual Basic 2005 (Microsoft Corporation, Redmond WA) as the front end.
Patient demographic details and history of symptoms data were collected during the registra-
tion process. Electronically generated CRFs were printed for each patient with the unique pa-
tient identifier number (barcode) and these were used to capture CXR, HIV, Xpert and FM
testing data which was entered into the data base described above by scanning the printed
unique identifier number. The database had five separate data entry screens to facilitate the
data capturing of the different Case Record Forms (CRFs). The Patient Barcode was used as a
unique identifier for all the tables and forms.
To facilitate linkage of the presumptive TB register data to the TB treatment register, a TB
register data base was designed that captured all patients who were notified during the study
period. Again the presumptive TB patient number was used as a unique identifier.
For analysis purposes, the data were linked to MS Access (Microsoft Corporation, Redmond
WA, USA) via Open Database Connectivity (ODBC) and exported to STATA for statistical
analysis (Stata Corporation Version 11. College Station, TX, USA). Initially a descriptive analy-
sis was conducted to describe the population that participated in the study. A flow diagram was
generated to show the flow of patients through the diagnostic process. To determine the time
to starting TB treatment, the presumptive TB treatment register data were linked to the TB
Algorithms for Xpert MTB/RIF
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treatment register. The time to starting TB treatment was defined as the number of days be-
tween the date of first presentation to the diagnostic services and the date the patient was com-
menced on TB treatment. To determine the changes that occurred to the notification data, a
before and after comparison was carried out to compare changes in absolute numbers of noti-
fied patients, and changes in proportions of pulmonary smear positive, pulmonary smear nega-
tive and extra-pulmonary TB as well as to determine the additional new bacteriologically
Fig 1. Flow of patients CXR algorithm.
doi:10.1371/journal.pone.0126376.g001
Algorithms for Xpert MTB/RIF
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confirmed TB cases commencing TB treatment after introduction of Xpert. The before period
included notification data from 2nd quarter 2010 to 1st quarter 2012 whilst the after period was
2nd quarter 2012 to 1st quarter 2014. Additional TB cases were calculated by subtracting notifi-
cations for the corresponding period prior to the implementation period and the % change was
calculated by dividing the additional cases found with the sum of notifications in the period be-
fore multiplied by 100. To demonstrate changes in proportions, pie charts were generated.
To determine if the observed changes in the proportion of bacteriologically confirmed cases
after the intervention were attributable to the introduction of Xpert or to changes in the distri-
bution of the TB suspect population, crude and adjusted proportions were calculated for new
bacteriologically confirmed pulmonary cases before and after introduction of the intervention
using new pulmonary TB cases as the denominator. Adjusted proportions were obtained using
direct standardisation on age, sex and HIV status. The standard population was defined as all
new pulmonary TB patients diagnosed during the before and after periods of the study for
that community.
Further analysis was done to understand how the numbers required to be screened by Xpert
would change if the CXR algorithm were used in combination with the HIV algorithm. As part
of the CXR algorithm diagnostic procedures and as already explained above, all presumptive
TB patients presenting to the CXR algorithm site were offered both CXR and HIV testing.
Using the available HIV data and CXR data from this site, a simulated algorithm was generated
that combined the CXR results with the HIV results. In this algorithm, the assumption made
was that patients would be screened with HIV first, followed by CXR to discriminate patients
into four groups of; 1) HIV positive with normal CXR; 2) HIV positive with abnormal CXR; 3)
HIV negative patients with normal CXR and 4) HIV negative with abnormal CXR. A further
assumption was made that only patients with abnormal CXR would have sputum tested whilst
those with a normal CXR would not have any further testing since it has been demonstrated
that the CAD program used in this study successfully identified patients who were list likely to
have TB.[32]
Proportions were compared using the chi-squared test whilst the continuous variables time
to starting TB treatment and age were compared using the T-test.
Results
CXR algorithm
Baseline results. At the study site where the CXR algorithm was tested, a total of 10,618
participants presented, of which 9889 (93.1%) met the definition of a presumptive TB patient
of cough of any duration. After excluding children aged 14 and less (380) and those who with-
drew, 9482 (95.9%) presumptive TB patients were included in the final analysis. Of these pre-
sumptive TB patients, 459 (4.8%) did not get a CXR done. The mean age of all study
participants was 36 (SD 12.0) and 4925 (51.9%) were HIV positive. Of the 4925 HIV positive
individuals, 3123 (63.4%) reported their HIV positive status as already known whilst 1802
(36.6%) were newly diagnosed. There were more males than females that presented for screen-
ing; 5853 (61.7%) compared to 3629 (38.3%) respectively (p<0.0001). The majority of patients,
6014 (63.4%) had a cough duration of 2 to 8 weeks. Among the 9023presumptive TB patients
who had a CXR done, 6568(72.8%) had an abnormal CXR whilst 2455 (27.2%) had a normal
CXR. (Fig 1 and Table 1)
TB case detection and time to TB treatment. Of the 9482 presumptive TB patients, 9074
had evaluable results. A total of 2223/9076(24.5%) presumptive TB patients had TB detected
by either Xpert or FM (Fig 1). Among those with abnormal CXR and valid Xpert result, Xpert
detected TB in 2090/6343 (32.9%) whilst among those with CXR not done, Xpert detected TB
Algorithms for Xpert MTB/RIF
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in 125/429 (29.1%).In those participants with a normal CXR, FM detected TB in 8/2304
(0.3%). Of the 8 TB cases detected by FM, 4 CXRs were read as being consistent with TB by the
radiographer whilst the CAD system scored them as normal, the rest were scored as normal by
both the radiographer and by CAD. (Fig 1)
The median time to starting treatment for those with bacteriologically confirmed TB was 1
day (IQR 1–3) (Table 2).
Empirical TB treatment. Among presumptive TB patients with an abnormal CXR in
whom TB was not detected by Xpert or did not have a sample tested, 1508/4478 (33.7%) were
empirically treated for TB (Fig 1). Among those with a CXR scored as normal in whom TB was
not detected by FM or did not get an FM test, 50/2447(2.0%) were empirically treated for TB.
The median time to starting TB treatment for bacteriologically unconfirmed individuals with
an abnormal CXR and tested with Xpert was 1 day (IQR 1–3 days) whilst for individuals with a
normal CXR tested with FM, it was 7 days (IQR 3–75) (Table 2).
Table 2. Median time to starting TB treatment.
Type of Patient CXR Algorithm Median-
days(IQR)
HIV algorithm
Median(IQR)
All 1(1–3) 3 (2–6)
Bacteriologically conﬁrmed GXP positive only FM
positive only
1(1–3) 1(1–3) 4.5 (3–6) 3(1–5) 2(1–5) 3(2–5)
Bacteriologically unconﬁrmed GXP negative only
FM negative only
1(1–3) 1(1–3) 7(3–75) 8(4–31) 12.5(5–33) 7
(4–25)
doi:10.1371/journal.pone.0126376.t002
Table 1. Baseline characteristics of study participants, CXR algorithm.
Total 9482(%)
Gender
Female 3629 (38.3)
Male 5853 (61.7)
Mean age(SD 36(SD12.0)
Chest X-ray
Abnormal CXR 6568 (69.3)
Normal CXR 2455 (25.9)
CXR not done 459 (4.8)
HIV status
HIV negative 4072 (42.9)
HIV positive (already known) 3123 (32.9%)
HIV positive (Newly diagnosed) 1802 (19.0%)
Unknown HIV status 485 (5.2)
Cough duration
Less than 2 weeks 2436 (25.7)
2–8 weeks 6014 (63.4)
> 8 weeks 943 (9.9)
Unknown duration 89 (0.9)
Previous TB treatment
Yes 2126 (22.4)
No 7349 (77.5)
Unknown 7(0.1)
doi:10.1371/journal.pone.0126376.t001
Algorithms for Xpert MTB/RIF
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Impact on notification. Using notification data, 1045 additional new bacteriologically
confirmed TB cases were notified during the intervention period compared to the period before
the intervention translating to a percentage change 110.0% from baseline. Additional all forms
of TB notified were 255 (6.0% change from baseline) (Fig 2). The notification rate for all forms
of TB notified was 1652/100,000/yr population before the interventions and 1403 /100,000/yr
population after the intervention using 2010 and 2012 population estimates respectively. The
notification rate of new bacteriologically confirmed TB was 368/100,000/yr population before
the intervention compared to 620/100,000/yr population after the intervention. (Fig 2A and
Table 3) The crude proportion of new bacteriologically confirmed cases among new pulmonary
TB cases before the intervention was 0.380 (95%CI 0.361–0.399) and after the intervention it
was 0.666 (95%CI 0.649–0.683). The adjustment for age, sex and HIV status did not change the
results significantly; 0.384 (95%CI 0.365–0.402) before the intervention and 0.667 (95%
CI0.650–0.683) after the intervention.
HIV algorithm
Baseline results. At the study site where the HIV algorithm was tested, a total of 5038 in-
dividuals presented for screening of which 4668 (92.7%) met the definition of a presumptive
Fig 2. Comparison of before and after case notification at the CXR algorithm site.
doi:10.1371/journal.pone.0126376.g002
Table 3. Crude and Adjusted proportions, new bacteriologically confirmed TB.
Community Total New Pulmonary TB Patients
(bacteriologically conﬁrmed)
Crude (95%CI) Age/Sex/HIV adjusted (95%
CI)
CXR Algorithm Before
After
4263
4518
2499 (950) 2995 (1995) 0.380 (0.361–0.399) 0.666
(0.649–0.683)
0.384 (0.365–0.402) 0.667
(0.650–0.683)
HIV Algorithm Before
After
1556
1392
696 (360) 976 (758) 0.517 (0.480–0.554) 0.776
(0.751–0.803)
0.515 (0.480–0.549) 0.779
(0.753–0.804)
doi:10.1371/journal.pone.0126376.t003
Algorithms for Xpert MTB/RIF
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TB patient (cough of any duration). After excluding children aged 14 years and less and those
that withdrew, 4444 were included in the final analysis.(Fig 3)The mean age of all study partici-
pants was 36 (SD 12.0) and 2265 (51.0%) were HIV positive. Of the 2265 HIV positive individ-
uals, 1620(71.5%) reported their HIV positive status as already known whilst 645 (28.5%) were
Fig 3. Flow of patients HIV algorithm.
doi:10.1371/journal.pone.0126376.g003
Algorithms for Xpert MTB/RIF
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newly diagnosed. There were more males than females that presented for screening; 2599
(58.5%) compared to 1845 (41.5%) (Fig 3 and Table 4)
TB case detection and time to TB treatment. Of 4444 presumptive TB patients, 4352 had
evaluable sputum results. A total of 763/4352 (17.5%) presumptive TB patients had TB de-
tected by either Xpert or FM. (Fig 3) Among the 2265 participants who were HIV positive,
Xpert detected 508 (22.8%) TB cases whilst among those 244 with unknown HIV status and
valid Xpert results, TB was detected in 43 (17.4%). FM was AFB positive among 212/1876
(11.3%) who were HIV negative (Fig 3).
A total of 537 patients received both Xpert and FM tests regardless of their HIV status.
Among these 238 (44.2%) were HIV negative of which FM was AFB positive in 22 (9.2%)
whilst Xpert detected TB in 31 (13.0%). Among the 216 HIV negative individuals that were FM
smear negative, Xpert detected TB in 13 (6.0%) individuals.
The overall median time to starting treatment for those with bacteriologically confirmed TB
was 3 days (IQR 2–6). The median time to starting treatment for those detected using Xpert
was 2 days (IQR 1–5) whilst for those detected using FM it was 3 days (IQR 2–5), (p = 0.072)
(Table 2)
Empirical TB treatment. Among presumptive TB patients with positive or unknown HIV
status in whom TB was not detected by Xpert or did not get an Xpert test done, 134/1972
(6.8%) were diagnosed with TB clinically and commenced on TB treatment. Among those with
a negative HIV status in whom TB was not detected by FM,100/1709 (5.8%) were diagnosed
with TB clinically and commenced on treatment. The overall median time to starting TB treat-
ment for bacteriologically negative individuals was 8 days (IQR 4–31). When restricted to
those with Xpert negative results, the median time to starting TB treatment was 12.5 days (IQR
5–32) whilst for those tested with FM it was 7 days (IQR 4–25) (p<0.0001)(Fig 3).
Impact on notification. Additional new bacteriologically confirmed TB cases notified
were 398 representing a 111% change from baseline. There was a reduction in all forms of TB
notified by 164 representing -11% change from baseline. The notification rate of new bacterio-
logically confirmed TB was 145/100,000/yr and 261/100,000/yr pre and post intervention
Table 4. Baseline characteristics of study participants, HIV algorithm.
Total 4444(%)
Gender
Female 1845 (41.5)
Male 2599 (58.5)
Mean age(SD 36.3(SD 12.1)
HIV Status
HIV negative 1920 (43.2)
HIV positive (already known) 1620 (36.5%)
HIV Positive (Newly Diagnosed) 645 (14.5%)
Unknown HIV status 259 (5.8)
Cough duration
Less than 2 weeks 1747 (39.4)
2–8 weeks 2286 (51.4)
> 8 weeks 351 (7.9)
Unknown duration 60 (1.3)
Previous TB
Yes 872 (19.6)
No 3572 (80.4)
doi:10.1371/journal.pone.0126376.t004
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respectively (Table 3). The notification rate for all forms of TB notified was 638/100,000/yr and
480/100,000/yr pre and post intervention respectively. (Fig 4, Table 3) The crude proportion of
new bacteriologically confirmed cases among new pulmonary TB cases before the intervention
was 0.517 (95%CI 0.480–0.554) and after the intervention it was 0.776 (95%CI 0.751–0.803).
The adjustment for age, sex and HIV status did not change the results significantly; 0.515 (95%
CI 0.480–0.549) before the intervention and 0.779 (95%CI 0.753–0.804) after the intervention.
Simulated algorithm: combined CXR and HIV algorithm
If the CXR and HIV algorithm are combined, out of the 9023 screened with HIV, 5131 (56.9%)
were HIV positive or status unknown. Among these HIV positive individuals, if they all under-
went CXR, 3983/5131 (77.6%) would have an abnormal CXR and these would be tested with
Xpert. Similarly of the 3892 that were HIV negative, 2585 had an abnormal CXR and would be
tested with FM. In this combined algorithm, 27.2% of those originally screened (2455/9023)
would not have their sputum tested with either Xpert or FM whilst 44.1% (3983/9023) would
be tested with Xpert and 28.7% (2585/9023) would be tested with FM (Fig 5).
Discussion
The overall detection of TB using either algorithm was surprisingly high in this population
where a widely inclusive definition of a presumptive TB patient was used; cough of any dura-
tion. This finding suggests that inadequate numbers of patients present for screening for TB
Fig 4. Comparison of before and after case notification at the HIV algorithm site.
doi:10.1371/journal.pone.0126376.g004
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and that there may be a pool of undiagnosed TB in the community even when a sensitive diag-
nostic tool, such as Xpert, is used in conjunction with case finding activities. This is also sup-
ported by the high number of abnormal CXRs among presumptive TB patients at the site
where the CXR algorithm was implemented. These findings suggest that the use of better TB
diagnostic tests will only have the desired impact if patients access diagnostic services in a time-
ly manner and will require broader investment in community, health services to extend com-
munity case finding activities.
The CXR unit with computerised scoring used in this study resulted in 27% patients not
being tested by Xpert. This is because the CAD program used to score CXRs was set to very
high sensitivity and low specificity in order not to miss cases. This means that large numbers of
patients still have to be tested with Xpert which may be a challenge for resource constrained
settings. However, If used in combination with HIV pre-screening followed by Xpert testing
only for those who are HIV positive with abnormal CXR, this would result in 56% patients not
being tested with Xpert which potentially can reduce the cost of diagnosis. The marginal costs
of digital CXR are small compared to the cost of cartridges. In a study to determine the sensitiv-
ity of the CAD program used in this study, done in the same population, it was found that indi-
viduals with a normal CXR score were unlikely to have TB, suggesting that no further
screening is required for individuals with a normal CXR regardless of their HIV status but vali-
dation studies are still required using culture as a reference standard as opposed to using Xpert
as was the case in this study.[32]In this combined algorithm, HIV negative individuals with an
abnormal CXR could be tested with FM thus improving the sensitivity of FM and reducing the
numbers needed to test. Doing FM test only in those individuals with abnormal CXR score
could improve the sensitivity of FM and also potentially reduce the overall cost of diagnosis.
The CXR algorithm used in this study has shown that it is possible to use CXR and Xpert
and still get a same day diagnosis and that placement of these diagnostic facilities at the point
of use is vital for reducing time to treatment. In this study, the time to starting treatment in
those with abnormal CXR and Xpert TB detected was one day and this is in contrast to
Fig 5. Simulated algorithm, combined HIV and CXR algorithm.
doi:10.1371/journal.pone.0126376.g005
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observations from settings where Xpert is placed centrally.[17, 39, 40] Further, same day em-
piric TB diagnosis and treatment was also possible. It has been observed previously that empir-
ic TB treatment initiation can take up to several weeks with a mean time to diagnosis of 13
days compared to 3 days for smear positive cases.[4, 41]The role of onsite placement of CXR in
reducing time to treatment has been observed by other studies conducted in the same popula-
tion.[19, 41]We also found that where CXR was not readily available (HIV algorithm site), a
longer time to empiric TB diagnosis and treatment was observed with an overall median time
to treatment of 8 days further highlighting the possible role availability of diagnostic tools at a
point of care have in reducing time to diagnosis.
Using HIV screening to pre-select patients so that only those who HIV are positive or HIV
status unknown accessed Xpert resulted in 43% patients not being tested with Xpert. If used
among HIV negative patients as a follow on test to smear, Xpert detected TB in 6% of those
who would have been missed by smear microscopy. The use of Xpert as a follow on test in
smear negative TB patients who are not suspected to have HIV associated TB is a conditional
recommendation by the WHO, but this poses ethical problems as well as resource problems.
Smear negative patients who do not have HIV associated suspected TB should be considered
for testing with Xpert as a follow on test to avoid delays in diagnosis and to prevent ongoing
transmission from these patients. However the feasibility of such a strategy would need to be
ascertained as it would require huge resource allocation to test large numbers of smear negative
TB patients to find 1 case of TB among this population. Use of CXR as a further screening tool
in smear negative HIV negative presumptive TB patients could reduce the number needing to
be screened with Xpert as a follow on test.
At both study sites, the proportion of pulmonary smear negative (empirically diagnosed)TB
expectedly reduced significantly after introduction of Xpert, however the overall number of
cases notified remained the same or decreased slightly. This suggests that some cases that
would have previously been diagnosed as smear negative were now diagnosed as bacteriologi-
cally confirmed cases and that there was likely to be reallocation of case status rather than in-
creased numbers of cases detected. It is not immediately clear why the extra pulmonary TB
diagnosis reduced drastically at the HIV algorithm site. The significant reduction in the num-
ber of extra-pulmonary TB diagnosis made after introduction of Xpert may explain the fall in
absolute numbers of TB cases starting treatment in this facility.
Time to empiric TB diagnosis and treatment for patients examined using Xpert was 7 days
longer than those examined by FM at the HIV algorithm site. These findings are contrary to
the expectation that clinicians would more likely make a diagnosis of TB in patients suspected
to have HIV associated TB especially in a high incidence setting. The proportion of patients
with empiric TB treatment was the same in both HIV negative and HIV positive patients,
again contrary to what would be expected.
The study has both limitations and strengths. The two sites were different, had different cli-
nicians, were accessed by different communities and different algorithms were used and there-
fore cannot be directly compared. However, the strengths of this study are that it was
conducted in high TB HIV setting area with Xpert placed at primary care sites within the rou-
tine health system. Data from these settings are scant and this study informs on how Xpert can
be used in these settings.
Conclusions
The routine use of Xpert in a resource-limited setting at primary care level resulted in addition-
al cases of confirmed TB patients starting treatment expectedly and increased notification rates
of bacteriologically confirmed TB cases. Same day diagnosis and treatment commencement
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was achieved for both bacteriologically confirmed and empirically diagnosed patients where
Xpert was used in conjunction with CXR. The HIV algorithm in this setting reduced the num-
ber tested by Xpert by 43% whilst the CXR algorithm reduced the number tested by 27%. The
CAD program used in this study was able to discriminate successfully between those with TB
and those without TB. If used in combination with the HIV algorithm, the numbers tested with
Xpert could be reduced by 56% whilst the numbers tested by FM could be reduced by 71%. The
marginal costs of digital X-ray are small compared to the cost of Xpert cartridges. Using the
recommended WHO algorithm alone results in missed cases among those who are HIV nega-
tive and therefore not tested by Xpert and use of Xpert as a second line test in these patients
should be considered though the feasibility and cost benefit of this strategy would have to be as-
certained in view of the huge resources that would be required to test large numbers of smear
negative patients to find 1 case of TB. The problem of missed cases can be reduced by using
CXR in combination with HIV testing to screen patients. Cost effectiveness of such strategies
would have to be ascertained.
Finally the findings in this study inform on the use of CXR as a pre-screening tool for active
TB as recommended by the WHO in their new recommendations for TB screening. [42] The
use of computerised scoring of CXRs has the potential to extend the use of CXR in resource
constrained settings which still face challenges of qualified staff to interpret CXR correctly and
thus has the potential to minimise the cost of TB diagnosis especially when used in conjunction
with expensive new diagnostic tools.
Supporting Information
S1 Data. Aggregated notification data.
(XLSX)
S2 Data. CXR algorithm data.
(CSV)
S3 Data. HIV algorithm data.
(CSV)
Acknowledgments
Frank Vijn is acknowledged (Delft Imaging) for the technical assistance with the digital X-ray
Unit. The authors would like to acknowledge project staff members for their role of data collec-
tion, and the staff of the Lusaka district health management board.
Author Contributions
Conceived and designed the experiments: PGF HAM. Muyoyeta. Performed the experiments:
M. Muyoyeta M. Moyo N. Kasese DMWMMN. Analyzed the data: M. Muyoyeta AS. Contrib-
uted reagents/materials/analysis tools: M. Muyoyeta M. Moyo N. Kasese DMWMMNN.
Kapata. Wrote the paper: PGF HAM. Muyoyeta M. Moyo N. Kasese DMWMMNN. Kapata
AS.
References
1. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in
people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes.
Lancet. 2007; 369(9578):2042–9. Epub 2007/06/19. doi: S0140-6736(07)60284-0 [pii] doi: 10.1016/
S0140-6736(07)60284-0 PMID: 17574096.
Algorithms for Xpert MTB/RIF
PLOS ONE | DOI:10.1371/journal.pone.0126376 June 1, 2015 15 / 18
2. World Health Organisation. Improving the diagnosis and treatment of smear-negative pulmonary and
extrapulmonary tuberculosis among adults and adolescents:Recommendations for HIV-prevalent and
resource-constrained settings World Health Organisation; 2007.
3. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuber-
culosis. Int J Tuberc Lung Dis. 2000; 4(2):97–107. PMID: 10694086.
4. Hudson CP, Wood R, Maartens G. Diagnosing HIV-associated tuberculosis: reducing costs and diag-
nostic delay. Int J Tuberc Lung Dis. 2000; 4(3):240–5. PMID: 10751070.
5. Parry CM, Kamoto O, Harries AD, Wirima JJ, Nyirenda CM, Nyangulu DS, et al. The use of sputum in-
duction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tuber
Lung Dis. 1995; 76(1):72–6. Epub 1995/02/01. PMID: 7718851.
6. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodefi-
ciency virus infection. N Engl J Med. 1991; 324(23):1644–50. Epub 1991/06/06. PMID: 2030721.
7. Mwandumba HC, Bertel Squire S, White SA, Nyirenda MH, Kampondeni SD, Rhoades ER, et al. Asso-
ciation between sputum smear status and local immune responses at the site of disease in HIV-infected
patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2008; 88(1):58–63. Epub 2007/10/05. doi:
S1472-9792(07)00067-4 [pii] doi: 10.1016/j.tube.2007.06.003 PMID: 17913585.
8. Hargreaves NJ, Kadzakumanja O, Whitty CJ, Salaniponi FM, Harries AD, Squire SB. 'Smear-negative'
pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.
Int J Tuberc Lung Dis. 2001; 5(9):847–54. PMID: 11573897.
9. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, et al. The impact of human immunode-
ficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc
Trop Med Hyg. 1995; 89(1):78–82. Epub 1995/01/01. PMID: 7747316.
10. Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, et al. Treatment outcome of
an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in
Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg. 1998; 92(3):343–7. Epub 1998/12/23. PMID:
9861414.
11. World Health Organisation. Rapid implementation of the Xpert MTB/RIF diagnostic test: Technical and
operational 'How- to'. Practical considerations (WHO/HTM/TB/2011.2) 2011 April. Report No.
12. World Health Organisation. Road map for rolling out Xpert MTB RIF for rapid diagnosis of TB and MDR-
TB 2010 [updated 8 December; cited 2014 20 June]. Available from: http://www.who.int/tb/laboratory/
roadmap_xpert_mtb-rif.pdf.
13. World Health Organisation. The Use of Liquid TB Culture and Drug Susceptibility Testing(DST) in Low
and Medium Income Settings. 2007.
14. Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement.
Geneva: World Health Organization.; 2011.
15. Van Rie A, Page-Shipp L, Scott L, Sanne I, StevensW. Xpert((R)) MTB/RIF for point-of-care diagnosis
of TB in high-HIV burden, resource-limited countries: hype or hope? Expert review of molecular diag-
nostics. 2010; 10(7):937–46. Epub 2010/10/23. doi: 10.1586/erm.10.67 PMID: 20964612.
16. Jaeger S, Karargyris A, Candemir S, Siegelman J, Folio L, Antani S, et al. Automatic screening for tu-
berculosis in chest radiographs: a survey. Quant Imaging Med Surg. 2013; 3(2):89–99. Epub 2013/05/
01. doi: 10.3978/j.issn.2223-4292.2013.04.03 qims-03-02-089 [pii]. PMID: 23630656; PubMed Central
PMCID: PMC3636475.
17. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert(R) MTB/RIF in centralised laboratories in South Af-
rica undermines potential impact. Int J Tuberc Lung Dis. 2012; 16(5):701; author reply 2. Epub 2012/
04/18. doi: 10.5588/ijtld.12.0131 PMID: 22507934.
18. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to treatment and patient
outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic
in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421. Epub 2013/06/14. doi: 10.1371/journal.
pone.0065421 PMID: 23762367; PubMed Central PMCID: PMCPmc3675091.
19. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clini-
cal effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a
multicentre, randomised, controlled trial. Lancet. 2014; 383(9915):424–35. Epub 2013/11/02. doi: 10.
1016/s0140-6736(13)62073-5 PMID: 24176144.
20. Naul LG, Sincleair ST. Radiology goes filmless. What does this mean for primary care physicians?
Postgrad Med. 2001; 109(6):107–10, 13. Epub 2001/06/27. PMID: 11424340.
21. Muto H, Tani Y, Suzuki S, Yokooka Y, Abe T, Sase Y, et al. Filmless versus film-based systems in ra-
diographic examination costs: an activity-based costing method. BMC Health Serv Res. 2011; 11:246.
Epub 2011/10/04. doi: 1472-6963-11-246 [pii] doi: 10.1186/1472-6963-11-246 PMID: 21961846;
PubMed Central PMCID: PMC3205032.
Algorithms for Xpert MTB/RIF
PLOS ONE | DOI:10.1371/journal.pone.0126376 June 1, 2015 16 / 18
22. Kurihara Y, Yoshida S, Geshi H, Kubo Y, Kitazoe Y. Economic analysis of a filmless system based on
the hospital information system. Stud Health Technol Inform. 2001; 84(Pt 2):1166–70. Epub 2001/10/
18. PMID: 11604913.
23. Maduskar P, Muyoyeta M, Ayles H, Hogeweg L, Peters-Bax L, van Ginneken B. Detection of tuberculo-
sis using digital chest radiography: automated reading vs. interpretation by clinical officers. Int J Tuberc
Lung Dis. 2013; 17(12):1613–20. Epub 2013/11/10. doi: 10.5588/ijtld.13.0325 PMID: 24200278.
24. Theron G, Pooran A, Peter J, van Zyl-Smit R, Kumar Mishra H, Meldau R, et al. Do adjunct tuberculosis
tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-
poor setting? Eur Respir J. 2012; 40(1):161–8. Epub 2011/11/15. doi: 09031936.00145511 [pii] doi: 10.
1183/09031936.00145511 PMID: 22075479.
25. van THAH, Onozaki I, Lonnroth K. Choosing algorithms for TB screening: a modelling study to compare
yield, predictive value and diagnostic burden. BMC Infect Dis. 2014; 14(1):532. Epub 2014/10/20. doi:
10.1186/1471-2334-14-532 PMID: 25326816.
26. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment un-
dermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet In-
fect Dis. 2014; 14(6):527–32. Epub 2014/01/21. doi: 10.1016/s1473-3099(13)70360-8 PMID:
24438820.
27. Gavin Churcgyard, Kerrigan McCarthy, Katherine L. Fielding, Wendy Stevens, Violet Chihota, Mark
Nicol, et al. Effect of Xpert MTB/RIF on Early Mortality in Adults With Suspected TB: A Pragmatic Ran-
domised Trial (Abstract 95). Top Antivir Med2014. p. 48.
28. Katherine L Fielding, Kerrigan MMcCarthy, Helen Cox, Linda Erasmus, Sibuse Ginindza, Anna Vas-
sall, et al. Xpert as the First-Line in South Africa: Yield, Initial Loss To Follow-up, Proportion Treated
(Abstract 96LB). Top Antivir Med2014. p. 48–9.
29. Catharina C Boehme Pamela Nabeta, Skenders Girts, Caceres Tatiana, Christel Lee, Alland David,
et al. First evaluation of Xpert MTB prototype assay for rapdi detection of pulmonary TB and MDR TB in
Peru and Latvia. IUATLD; October 2008; ParisOctober 2008.
30. Naidoo S (Lancet Laboratories South Africa). Evaluation of GeneXpert MTB/RIF Assay on pulmonary
and extrapulmonary samples in a high throughput routine laboratory. ECCMID; ViennaApril 2010.
31. World Health Organisation. Guidelines for intensified tuberculosis case-finding and isoniazid preventive
therapy for people living with HIV in resource constrained settings. Geneva: World Health Organisa-
tion, 2011.
32. Muyoyeta M, Maduskar P, Moyo M, Kasese N, Milimo D, Spooner R, et al. The sensitivity and specifici-
ty of using a computer aided diagnosis program for automatically scoring chest X-rays of presumptive
TB patients compared with Xpert MTB/RIF in Lusaka Zambia. PLoS ONE. 2014; 9(4):e93757. Epub
2014/04/08. doi: 10.1371/journal.pone.0093757 PMID: 24705629; PubMed Central PMCID:
PMC3976315.
33. Hogeweg L, Mol C, de Jong PA, Dawson R, Ayles H, van Ginneken B. Fusion of local and global detec-
tion systems to detect tuberculosis in chest radiographs. Medical image computing and computer-as-
sisted intervention: MICCAI International Conference on Medical Image Computing and Computer-
Assisted Intervention. 2010; 13(Pt 3):650–7. Epub 2010/10/01. PMID: 20879456.
34. van Ginneken B, Stegmann MB, Loog M. Segmentation of anatomical structures in chest radiographs
using supervised methods: a comparative study on a public database. Med Image Anal. 2006; 10
(1):19–40. Epub 2005/05/28. doi: S1361-8415(05)00036-8 [pii] doi: 10.1016/j.media.2005.02.002
PMID: 15919232.
35. Arzhaeva Y, Tax DM, van Ginneken B. Dissimilarity-based classification in the absence of local ground
truth: Application to the diagnostic interpretation of chest radiographs. Pattern Recognition. 2009; 42
(9):1768–76.
36. Duda RO, Hart PE, Stork DG. Pattern classification: JohnWiley & Sons; 2012.
37. Cepheid. Xpert MTB/RIF:Two-hour detection of MTB and resistance to rifampicin. Cepheid; 2009. p. 3–
4.
38. Rieder HL, van Deun A, Kam KM, Kim SJ, Chonde TM, Trébucq A, et al. Priorities for Tuberculosis Bac-
teriology Services in Low-Income Countries. Second edition ed. Union) IUATaLDT, 68 Boulevard
Saint-Michel P, France, editors: International Union Against Tuberculosisand Lung Disease (The
Union); 2007 February 2007.
39. Cohen GM, Drain PK, Noubary F, Cloete C, Bassett IV. Diagnostic Delays and Clinical Decision Making
With Centralized Xpert MTB/RIF Testing in Durban, South Africa. J Acquir Immune Defic Syndr. 2014;
67(3):e88–93. Epub 2014/10/15. doi: 10.1097/qai.0000000000000309 PMID: 25314255; PubMed
Central PMCID: PMC4197409.
40. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tu-
berculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a
Algorithms for Xpert MTB/RIF
PLOS ONE | DOI:10.1371/journal.pone.0126376 June 1, 2015 17 / 18
prospective study. PLoS Med. 2011; 8(7):e1001067. Epub 2011/08/06. doi: 10.1371/journal.pmed.
1001067 PMEDICINE-D-11-00362 [pii]. PMID: 21818180; PubMed Central PMCID: PMC3144215.
41. Zachary D, Schaap A, Muyoyeta M, Mulenga D, Brown J, Ayles H. Changes in tuberculosis notifications
and treatment delay in Zambia when introducing a digital X-ray service. Public Health Action. 2012; 2
(3):56–60.
42. World Health Organization. Systematic screening for active tuberculosis: principles and recommenda-
tions: World Health Organization; 2013.
Algorithms for Xpert MTB/RIF
PLOS ONE | DOI:10.1371/journal.pone.0126376 June 1, 2015 18 / 18
